Study of biochemical parameters in metabolic bone disease with chronic renal failure
Keywords:Metabolic bone disease, Chronic renal failure, Isoenzymes, Alkaline phosphatase
Background: Renal osteodystrophy and metabolic bone disease are terms that encompass a number of skeletal abnormalities, including osteomalasia, osteitis fibrosa cystica and impaired bone growth in children. The proposed work aimed to evaluate the status of bone health by estimating levels of elements like calcium, phosphorus, magnesium, alkaline phosphatase and alkaline phosphatase isoenzymes in serum of patients suffering from metabolic bone disease with chronic renal failure.
Methods: The routine biochemical investigations were estimated by known standard methods and alkaline phosphatase isoenzymes were done by polyacrylamide slab gel electrophoresis. The assay values were statistically validated.
Results: Serum calcium levels were significantly decreased (p<0.001) in chronic renal failure cases than control whereas, phosphorus and serum alkaline phosphatase levels were significantly increased. Electrophoresis on polyacrylamide gel separated the serum alkaline phosphatase isoenzymes. In control group, two bands of isoenzymes appeared. Whereas, in patients with metabolic bone disease with chronic renal failure, only one diffused band appeared.
Conclusions: Decreased calcium levels and increased phosphorus levels in serum indicate metabolic bone disease with chronic renal failure. Elevation of serum alkaline phosphatase is a marker of sick bone. Increased levels of serum alkaline phosphatase are responsible for appearance of diffused band of isoenzyme which is marker for metabolic bone disease with chronic renal failure.
Franke-S, Lehmann-G, Abendroth-K, Hein-G, Stein-G. PICP as bone formation and NTx as bone resorption marker in patients with chronic renal failure. Eur J Med Res. 1998;3(1-2):81-8.
Morion-K, Koide-K. Secondary hyperparathyroidism and tertiary hyperparathyroidism in chronic renal failure, uremia. Nippon- Rinsho. 1995;53(4):958-64.
Alper S-DH, DeSchryver- Kecskemeti-K, Goodwin-CL, Tindira-CA, Harter-H, Slatopolsky-E. Intestinal alkaline phosphatase in patients with chronic renal failure. Gastroenterol. 1988;94(1):62-7.
Tsumura M, Ueno Y, Kinouchi T, Koyama I, Komoda T. Atypical alkaline phosphatase isoenzymes in serum and urine of patients with renal failure. Clin Chim Acta. 2001;312(1-2):169-78.
Meema HE, Oreopoulos DG, Rapoport A. Serum magnesium level and arterial calcification in end stage renal disease. Kidney Int. 1987;32(3):388-94.
Lindeman RD. Chronic renal failure and magnesium metabolism. Magnesium. 1986;5(5-6):293-300.
Trinder P. Colorimetric micro-determination of calcium in serum. Analyst. 1960;85:889-94.
Fiske CH, Subbarow Y. The colorimetric determination of phosphorus. J Biol Chem. 1925;66:375.
Neill DW, Neely RA. The estimation of magnesium in serum by titan yellow. Clin Path. 1956;(9):162.
Kind PRN, King EJ. Estimation of plasma phosphatase by determination of hydrolysed phenol with amino-antipyrine. J Clin Pathol. 1954;7(4):322-6.
Smith I, Lightstone PJ, Perry JD. Separation of human tissues alkaline phosphatases by electrophoresis on acrylamide disc gels. Clin Chim Acta. 1968;(19):499-505.
Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25 DHCC in uremic patients. J Clin Invest. 1984;74:2136-43.
Bricker NS, Slatopolsky E, Reiss E, Avioli LV. Calcium, phosphorus and bone in renal disease and transplantation. Arch Intern Med. 1969;123:543-53.
Mountokalokis TD. Magnesium metabolism in chronic renal failure. Magnes Res. 1990;3(2):121-7.
Leibovitch I, Ben-Chaim J, Ramon J, Goldwasser B. Increased serum alkaline phosphatase activity: a possible indicator of renal damage. J Clin Lab Anal. 1991;5(6):406-9.